Date: 2012-10-03
Type of information: Distribution agreement
Compound: defibrotide
Company: Gentium (Italy) Biologix FZCo (United Arab Emirates)
Therapeutic area: Digestive diseases - Liver diseases - Transplantation
Type agreement: distribution
Action mechanism: Defibrotide is a polydeoxyribonucleotide isolated from pig intestine. It is believed to have antithrombotic properties.
Disease: prevention and treatment of hepatic veno-occlusive disease (VOD)
Details: Gentium has announced the appointment of Biologix FZCo as the exclusive distributor of Defibrotide in the Middle East and North Africa (MENA). Under the terms of the agreement, which is valid for 10 years, Biologix will be responsible for managing named-patient requests and obtaining price and reimbursement approvals in the MENA region. Following regulatory approval to market Defibrotide, if any, Biologix will be responsible for sales, marketing and local medical affairs activities in this region.
Biologix FZCo, a company established under the laws of UAE in 2003, provides for the distribution and marketing of biotech products in the MENA region. Equipped with a logistics hub based in Dubai Airport Free Zone and supported by a qualified workforce, it offers effective Regulatory, Medical, Marketing, Sales and Distribution support to its partners with a direct and adequate presence in 17 countries of the Middle East and North Africa including Saudi Arabia, UAE, Kuwait, Bahrain, Oman, Qatar, Yemen, Iran, Iraq, Lebanon, Syria, Jordan, Egypt, Libya, Tunisia, Algeria, and Morocco. Biologix’ main therapeutic focuses are Oncology-Hematology, Central Nervous System and Rare Diseases.
Financial terms:
Latest news:
